Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,201–2,300 of 4,275
Chronic Infections: A Possible Scenario for Autophagy and Senescence Cross-Talk
Aguilera, M. O., Delgui, L. R., Romano, P. S., & Colombo, M. I. (2018) · Cells · doi:10.3390/cells7100162 · Cited by 21
“Once activated, senescent cells undergo morphological and functional modifications, which include arrest of proliferation, the resistance to apoptotic signals, size increasing, alteration in gene expression, and activation f SASP.”
BackgroundInfluentialGuarnera, L., Santinelli, E., Galossi, E., Cristiano, A., Fabiani, E., Falconi, G., & Voso, M. T. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.09.005 · Cited by 22
Cellular microenvironment: a key for tuning mesenchymal stem cell senescence
Sun, W., Lv, J., Guo, S., & Lv, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1323678 · Cited by 22
Miyahara, S., Ohuchi, M., Nomura, M., Hashimoto, E., Soga, T., Saito, R., Hayashi, K., Sato, T., Saito, M., Yamashita, Y., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107678 · Cited by 24
Cellular senescence associated immune responses in liver cancer
Greten, T. F., & Eggert, T. (2017) · Hepatic Oncology · doi:10.2217/hep-2017-0011 · Cited by 21
Parvizi, M., Ryan, Z. C., Ebtehaj, S., Arendt, B. K., & Lanza, I. R. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165983 · Cited by 20
Quantitative Analysis of Cellular Senescence in Culture and In Vivo
Zhao, J., Fuhrmann‐Stroissnigg, H., Gurkar, A. U., Flores, R. R., Dorronsoro, A., Stolz, D. B., Croix, C. M. S., Niedernhofer, L. J., & Robbins, P. D. (2017) · Current Protocols in Cytometry · doi:10.1002/cpcy.16 · Cited by 22
Heath, J., Fudge, N. J., Gallant, M., & Grant, M. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00201 · Cited by 23
“We then selectively examined the telomeres of CMV-specific CD8+ T cells and other lymphocytes from a subset of these individuals for progress toward replicative senescence and potential acquisition of a senescence-associated secretory phenotype (SASP) (33).”
MethodInfluentialDietary flavonoid actions on senescence, aging, and applications for health
Watkins, B. A., Mitchell, A. E., Shin, A. C., Dehghani, F., & Shen, C. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109862 · Cited by 24
Margheri, F., Menicacci, B., Laurenzana, A., Rosso, M. D., Fibbi, G., Cipolleschi, M. G., Ruzzolini, J., Nediani, C., Mocali, A., & Giovannelli, L. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.12.026 · Cited by 19
“…of the senescent cell, i.e. the increased secretion of inflammatory and growth factors, known as the “senescence-associated-secretory-phenotype” (SASP), found to play a role in many age-related diseases, and to cooperate in inducing a tumor-favoring cell micro-environment (Coppé et al., 2008).”
BackgroundMa, Y., Liang, Y., Liang, N., Zhang, Y., & Xiao, F. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.111908 · Cited by 20
Cellular Senescence in Non-Small Cell Lung Cancer
Zhu, H., Sun, J., Zhang, C., Li, P., Tan, C., Yang, M., & Zhao, G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812357 · Cited by 21
A New Landscape of Human Dental Aging: Causes, Consequences, and Intervention Avenues
Xie, Y., Chen, S., Sheng, L., Sun, Y., & Liu, S. (2022) · Aging and Disease · doi:10.14336/ad.2022.1224 · Cited by 32
“The SASP is usually composed of multiple soluble factors, including but not limited to interleukins, chemokines, growth factors, metallo- proteases, and insoluble extracellular matrix components [16].”
BackgroundInfluentialSelf-citationSenescence of alveolar stem cells drives progressive pulmonary fibrosisPreprint
Yao, C., Guan, X., Carraro, G., Parimon, T., Liu, X., Huang, G.-L., Soukiasian, H., David, G., Weigt, S., Belperio, J., et al. (2019) · bioRxiv · doi:10.1101/820175 · Cited by 21
“The senescence-associated secretory phenotype (SASP) has been shown to promote cell proliferation (85-87), stimulate cell motility (invasion, migration) (88-90), regulate cell differentiation (32, 88-90), and affect leukocyte infiltration (91-93), all of which serve important roles in repair following acute injury yet…”
BackgroundIdentification of a small molecule SR9009 that activates NRF2 to counteract cellular senescence
Gao, L., Wang, Y., Liu, Z., Sun, Y., Cai, P., & Jing, Q. (2021) · Aging Cell · doi:10.1111/acel.13483 · Cited by 22
Self-citationPignolo, R. J. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220012 · Cited by 56
“Senescent cells have a modified secretome or SASP that is composed of signaling factors (e.g., cytokines), proteases (e.g., matrix metalloproteases), extracellular matrix proteins, nonprotein constituents (e.g., ROS), and extracellular vesicles, some of which contain miRNAs (45, 92).”
Huart, C., Fransolet, M., Demazy, C., Calvé, B. L., Lucas, S., Michiels, C., & Wéra, A.-C. (2022) · Cancers · doi:10.3390/cancers14061460 · Cited by 23
“Cancer cells incubated with a conditioned medium of senescent cells demonstrated a higher capacity to invade the basement membrane [48].”
BackgroundThe context-dependent effect of cellular senescence: From embryogenesis and wound healing to aging
Lavarti, R., Alvarez-Diaz, T., Marti, K., Kar, P., & Raju, R. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102760 · Cited by 21
Senescence-Associated Gene YPEL3 Is Downregulated in Human Colon Tumors
Tuttle, R., Simon, M., Hitch, D. C., Maiorano, J. N., Hellan, M., Ouellette, J. R., Termuhlen, P. M., & Berberich, S. J. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1558-x · Cited by 18
Xiao, M., Chen, W., Wang, C., Wu, Y., Zhu, S., Zeng, C., Cai, Y., Liu, C., & He, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.23622 · Cited by 21
“Among all these components, IL-6 and IL-8 plays a major role in such induction [19].”
BackgroundDong, Y.-L., Vadla, G. P., Lu, J., Ahmad, V., Klein, T. J., Liu, L., Glazer, P. M., Xu, T., & Chabu, C. Y. (2021) · Communications Biology · doi:10.1038/s42003-021-01898-5 · Cited by 21
Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem
Smigiel, J. M., Taylor, S. E., Bryson, B. L., Tamagno, I., Polak, K. L., & Jackson, M. W. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.26 · Cited by 20
“conditions, the SASP-factors act in an autocrine manner to maintain the senescence program and recruit immune cells into the local environment([80-83]).”
BackgroundNovel Approaches to Immunomodulation for Solid Organ Transplantation
Husain, I., & Luo, X. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-034012 · Cited by 24
Influences of Aged Bone Marrow Macrophages on Skeletal Health and Senescence
Pappert, M., Khosla, S., & Doolittle, M. L. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00820-8 · Cited by 25
Niu, Q., Li, D., Zhang, J., Piao, Z., Xi, Y., Xi, Y., Kamal, N. N. S. N. M., Lim, V., Li, P., & Yin, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102593 · Cited by 21
Hartmann, C., Herling, L., Hartmann, A., Köckritz, V., Fuellen, G., Walter, M., & Hermann, A. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1129107 · Cited by 24
“For studying SASP activation, reflecting senescent cells (Coppé et al., 2008), we examined secreted concentrations of two principle SASP factors, the inflammatory cytokines interleukin 6 (IL-6) and interleukin 8 (IL-8) in conditioned medium of donor cells by ELISA (Figures 2I, J).”
BackgroundSasaki, M., & Nakanuma, Y. (2011) · International Journal of Hepatology · doi:10.1155/2012/452143 · Cited by 19
“Furthermore, our recent study revealed that CCL2 expressed by senescent BECs can induce the cell migration of hepatic stellate cells (HSCs), which may play a role in the periportal fibrosis in chronic advanced liver diseases [52].”
BackgroundAssociation Between Atopic Dermatitis and Aging: Clinical Observations and Underlying Mechanisms
Chen, P., Shen, M., Cai, S., & Tang, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s467099 · Cited by 22
“155 Consequently, senescent cells themselves may partially contribute to AD progression.”
BackgroundThe Role of HSF1 and the Chaperone Network in the Tumor Microenvironment
Grunberg, N., Levi-Galibov, O., & Scherz‐Shouval, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-40204-4_7 · Cited by 16
Hajri, L., Lewińska, A., Rzeszutek, I., Oklejewicz, B., Wojnarowska‐Nowak, R., Krogul-Sobczak, A., Szpyrka, E., Aires, A., Ghodbane, S., Ammari, M., et al. (2024) · Cancers · doi:10.3390/cancers16091750 · Cited by 21
“These results may be considered as a side effect of the use of the microcapsule-based drug delivery system, as increased levels of IL8 may potentiate a senescence-associated secretory phenotype (SASP), a hallmark of cellular senescence [35,41].”
BackgroundAging Biomarkers and Novel Targets for Anti-Aging Interventions
Xu, K., Guo, Y., Li, Z., & Wang, Z. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-25650-0_3 · Cited by 26
Ahn, S. H., Cho, S.-M., Song, J., Kim, S., Oh, S. S., Jung, S., Cho, K. A., & Lee, T. (2016) · Molecular Oral Microbiology · doi:10.1111/omi.12167 · Cited by 21
Tang, C., Chen, H., Jiang, L., & Liu, L. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9018811 · Cited by 23
Fukuda, R., Suico, M. A., Koyama, K., Omachi, K., Kai, Y., Matsuyama, S., Mitsutake, K., Taura, M., Morino‐Koga, S., Shuto, T., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442442 · Cited by 20
Shackel, N. A., Vadas, M. A., Gamble, J. R., & McCaughan, G. W. (2013) · Hepatology · doi:10.1002/hep.26932 · Cited by 20
“1).(4) Inflammatory-associated obesity-related liver injury, nonalcoholic steatohepatitis (NASH) is associated with cirrhosis and hepatocellular carcinoma (HCC) formation.”
Backgroundp53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance
Souza, L. C. D. M. E., Faletti, A., Veríssimo, C. P., Stelling, M. P., & Borges, H. L. (2022) · Membranes · doi:10.3390/membranes12020202 · Cited by 20
“As outlined above, wtp53 drives senescence in response to multiple stress signals while restricting SASP activity, particularly its pro-tumorigenic potential [43,79].”
BackgroundHughes, B. K., Wallis, R., & Bishop, C. L. (2023) · Cell and Tissue Research · doi:10.1007/s00441-023-03768-4 · Cited by 19
Loss of HuR leads to senescence-like cytokine induction in rodent fibroblasts by activating NF-κB
Hashimoto, M., Tsugawa, T., Kawagishi, H., Asai, A., & Sugimoto, M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.07.005 · Cited by 22
Aging at the Crossroads of Organ Interactions: Implications for the Heart
Sen, I., Trzaskalski, N. A., Hsiao, Y., Liu, P. P., Shimizu, I., & Dérumeaux, G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325637 · Cited by 23
Cellular senescence in vivo: From cells to tissues to pathologies
Kumar, A., Bano, D., & Ehninger, D. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111308 · Cited by 20
Fu, J., Huang, D., Yuan, F., Xie, N., Li, Q., Sun, X., Zhou, X., Li, G., Tong, T., & Zhang, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001684 · Cited by 20
“To further explore TIFA-associated secretory changes, we screened a panel of senescence-associated secretory phenotype factors identified previously (2), and found the mRNA expression levels of IL-11, CCL5, CXCL3, CXCL10, GM-CSF, MCP1, and ICAM-1were potently induced by DNA insults in the presence TIFA promotes DNA da…”
BackgroundTarallo, D., Martínez, J., Leyva, A., Mónaco, A., Perroni, C., Tassano, M. R., Gambini, J. P., Cappetta, M., Durán, R., Moreno, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51427-7 · Cited by 21
Wu, S., Dai, X., Xia, Y., Zhao, Q., Heng, Z., Shi, Z., Yin, X., Liu, X., Zhang, A., Yao, Z., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114111 · Cited by 22
Vjetrovic, J., Shankaranarayanan, P., Mendoza-Parra, M. A., & Gronemeyer, H. (2014) · Aging Cell · doi:10.1111/acel.12197 · Cited by 21
“As IL6 has been identified as one of the key factors involved in paracrine mechanisms governed by senescent cells (Coppe et al., 2008; Kuilman et al., 2008), we tested early on whether IL6 could be the factor that induces the acquisition of TRAIL sensitivity.”
BackgroundMethodInfluentialHCSGD: An integrated database of human cellular senescence genes
Dong, Q., Han, H., Liu, X., Wei, L., Zhang, W., Zhao, Z., Zhang, M. Q., & Wang, X. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.04.001 · Cited by 24
“57 In order to understand cellular senescence in depth, a lot of efforts have been made to 58 reveal its mechanism, especially to identify the functional genes and microRNAs in this 59 M AN US CR IP T AC CE PT ED process (Coppe et al., 2008; Overhoff et al., 2014).”
BackgroundLuca, F. D., Camporeale, V., Leccese, G., Cuttano, R., Troise, D. E., Infante, B., Stallone, G., Netti, G. S., & Ranieri, E. (2025) · Cells · doi:10.3390/cells14221831 · Cited by 28
“Moreover, several studies have shown that the SASP evolves over time: in the early stages it may include factors that promote tissue repair and immune clearance of senescent cells, whereas in later stages it shifts toward a more pro-inflammatory and fibrotic profile [32].”
Ueno, M., Asada, K., Toda, M., Schlötzer-Schrehardt, U. M., Nagata, K., Montoya, M. M., Sotozono, C., Kinoshita, S., & Hamuro, J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19806 · Cited by 20
Metabolomics study of fibroblasts damaged by UVB and BaP
Yang, X., Wang, J., Wang, H., Li, X., He, C., & Liu, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-90186-7 · Cited by 23
Kim, S. H., Kim, J. W., Hwang, I. G., Jang, J. S., Hong, S., Kim, T. Y., Baek, J. Y., Shin, S. H., Sun, D. S., Hong, D.-S., et al. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.03.015 · Cited by 19
Iron Metabolism in Cancer and Senescence: A Cellular Perspective
Crescenzi, E., Leonardi, A., & Pacifico, F. (2023) · Biology · doi:10.3390/biology12070989 · Cited by 20
Goh, K. J., Chen, J., Rocha, N., & Semple, R. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-64136-8 · Cited by 22
Marzetti, E., Calvani, R., Landi, F., Coelho‐Júnior, H. J., & Picca, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137305 · Cited by 26
“Aging cells acquire ultrastructural and functional characteristics (i.e., multinucleated morphology, enlarged nucleus and vacuoles, damage to macromolecules, plasma membrane alterations, and high lysosomal activity) that culminate in a cascade of events leading to the development of SASP [9,57–61].”
BackgroundRIG-I-driven CDKN1A stabilization reinforces cellular senescence
Wang, C., Jiang, X., Li, H., Hu, J., Ji, Q., Wang, Q., Liu, X., Huang, D., Yan, K., Zhao, L., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2844-8 · Cited by 21
“…as initiators in the innate immune response followed by a batch of type I interferons (IFNs) and inflammatory cytokines released which is called senescence-associated secretory phenotype (SASP) (Coppé et al., 2008; Krizhanovsky et al., 2008; Coppé et al., 2010; Zhu et al., 2021;Liu et al., 2023).”
Accumulation of pTreg cells is detrimental in late‐onset (aged) mouse model of multiple sclerosis
Wang, W., Thomas, R. G., Oh, J., & Su, D. (2022) · Aging Cell · doi:10.1111/acel.13630 · Cited by 18
“…cells attack selftissues inducing inflammation, thereby enhancing senescent somatic cell secretions, which underlie chronic inflammation (termed senescence- associated secretory phenotype, SASP; Callender et al., 2018; Coppe et al., 2008, 2010) in the elderly (termed inflammaging; Giunta, 2006).”
BackgroundLiu, Z., Zhang, Y., Li, D., & Fu, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116463 · Cited by 20
Ex vivo generation of platelet products from human iPS cells
Nakamura, S., Sugimoto, N., & Eto, K. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00139-2 · Cited by 16
Altered Gene Expression of Muscle Satellite Cells Contributes to Agerelated Sarcopenia in Mice
Budai, Z., Balogh, L., & Sarang, Z. (2018) · Current Aging Science · doi:10.2174/1874609811666180925104241 · Cited by 17
Imran, S. A. M., Yazid, M. D., Idrus, R. B. H., Maarof, M., Nordin, A., Razali, R. A., & Lokanathan, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083888 · Cited by 20
“Meanwhile, addition of IL-6 and IL-8 to the pre-senescent cell-conditioned medium appeared to result in the promotion of cancer cell invasion [59].”
BackgroundAn evaluation of aging measures: from biomarkers to clocks
Wang, Q., Hou, T., Wang, Q., He, J., Wang, L., Si, J., & Chen, S. (2022) · Biogerontology · doi:10.1007/s10522-022-09997-4 · Cited by 19
“The composition of SASP is complex and includes a range of inflammatory cytokines, chemokines, growth factors, and proteases (Coppé et al. 2008).”
BackgroundDong, Y., Liu, G., Situ, X., Lei, X., Zhang, T., Zhu, X., Jin, H., Liu, Y., & Shou, S. (2024) · Inflammation · doi:10.1007/s10753-024-02081-8 · Cited by 23
DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes
Gomez-Sarosi, L., Sun, Y., Coleman, I. M., Bianchi-Frias, D., & Nelson, P. S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0387 · Cited by 17
“and matricellular proteins that are altered in benign cells following genotoxic stress or in the context of cellular senescence (13, 18, 19).”
BackgroundInfluentialSelf-citationStress-induced cellular senescence contributes to chronic inflammation and cancer progression.
KOBASHIGAWA, S., M. SAKAGUCHI, Y., MASUNAGA, S., & MORI, E. (2019) · Thermal Medicine · doi:10.3191/thermalmed.35.41 · Cited by 18
Does senescence play a role in age-related macular degeneration?
Malek, G., Campisi, J., Kitazawa, K., Webster, C. M., Lakkaraju, A., & Skowronska‐Krawczyk, D. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109254 · Cited by 18
Self-citationProspects of Disease-Modifying Osteoarthritis Drugs
Oo, W. M. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.003 · Cited by 20
Kaplon, J., Cornelia, H.-H., Gao, L. Y., Meissl, K., Verdegaal, E. M. E., van der Burg, S. H., van Doorn, R., & Peeper, D. S. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12248 · Cited by 21
Togtema, M., Hussack, G., Dayer, G., Teghtmeyer, M. R., Raphael, S., Tanha, J., & Zehbe, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092088 · Cited by 20
Senescence as a main mechanism of Ritonavir and Ritonavir‐NO action against melanoma
Paskaš, S., Krajnović, T., Basile, M. S., Đunđerović, D., Cavalli, E., Mangano, K., Mammana, S., Al‐Abed, Y., Nicoletti, F., Mijatović, S., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23020 · Cited by 18
Restoration of hair follicle inductive properties by depletion of senescent cells
Pappalardo, A., Kim, J. Y., Abaci, H. E., & Christiano, A. M. (2024) · Aging Cell · doi:10.1111/acel.14353 · Cited by 21
“…slowly accumulate senescent cells during passage (Raffetto et al., 1999 ), and are extensively studied in the field of senescence (Contrepois et al., 2017; Coppe et al., 2008; Idda et al., 2020; Jo et al., 2020; Kong et al., 2023; Rube et al., 2021; Waldera Lupa et al., 2015; Wang et al., 2009 ).”
Senescent CD8+ T cells: a novel risk factor in atrial fibrillation
Li, X., Bao, Y., Zhang, N., Lin, C., Xie, Y., Wei, Y. Z., Luo, Q., Liu, J., Sha, Z., Wu, G., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae222 · Cited by 20
The Dual Role of Senescence in Pancreatic Ductal Adenocarcinoma
Porciuncula, A., Hajdu, C. H., & David, G. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.006 · Cited by 20
Loss of p16: A Bouncer of the Immunological Surveillance?
Leon, K. E., Tangudu, N. K., Aird, K. M., & Buj, R. (2021) · Life · doi:10.3390/life11040309 · Cited by 22
Selim, A. M., Nooh, M. M., El‐Sawalhi, M. M., & Ismail, N. A. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110982 · Cited by 21
Merk, D., Cox, F. F., Jakobs, P., Prömel, S., Altschmied, J., & Haendeler, J. (2024) · Antioxidants · doi:10.3390/antiox13040443 · Cited by 21
A large-scale CRISPR screen and identification of essential genes in cellular senescence bypass
Liu, X., Wei, L., Dong, Q., Liu, L., Zhang, M. Q., Xie, Z., & Wang, X. (2019) · Aging · doi:10.18632/aging.102034 · Cited by 21
“45 SASP genes identified in previous studies [30, 31] were significantly elevated in senescent cells compared with growing cells (Supplementary Table 3), and the expression of these genes differed across the senescence bypass cells (Figure 4D, 4E).”
Backgroundp16ink4a Positivity of Melanocytes in Non-Segmental Vitiligo
Lee, J. W., Kim, T. H., Park, T. J., & Kang, H. Y. (2020) · Diagnostics · doi:10.3390/diagnostics10110878 · Cited by 18
“Recent evidence has shown that SASP is partially responsible for the persistent low-level chronic inflammation known as sterile inflammation [28–30].”
BackgroundInfluentialFrom Neuron‐Centric to Glia‐Centric: How Aging Glial Networks Drive Neurodegenerative Disease
Hayashide, L. D. S., Pessoa, B., Dias, G. R., Pontes, B., Pinto, R. S., & Diniz, L. P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70361 · Cited by 21
“The expression of these factors can be detected using complementary approaches, including RT-qPCR, ELISA, multiplex immunoassays, and transcriptomic analyses such as RNA-seq and has been widely employed as an indicator of senescence in studies of aging and chronic inflammation (Coppé et al. 2008).”
Negorev, D. G., Vladimirova, O. V., Kossenkov, A. V., Nikonova, E. V., Demarest, R. M., Capobianco, A. J., Showe, M. K., Rauscher, F. J., Showe, L. C., & Maul, G. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1483 · Cited by 21
“damage, when senescent fibroblasts begin secreting IL-6, IL-8, and other cytokines that promote transformation of epithelial cells (7).”
BackgroundRetractedWhite, E. E., & Rhodes, S. D. (2024) · Cancers · doi:10.3390/cancers16050994 · Cited by 22
“The SASP is induced via NF-κ B, p53, C/EBP-dependent transcriptional programs that promote the secretion of pro-inflammatory cytokines and chemokines, including IL-6, IL-7, IL-8, and IFNs [77].”
BackgroundMacDonald, J. A., Bradshaw, G. A., Jochems, F., Bernards, R., & Letai, A. G. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-024-01431-1 · Cited by 27
“…detection of senescence-associated β -galactosidase (SA-β gal) [16], predictable changes in gene expression regulation to suspend proliferation [17], as well as the secretion of growth factors and other cytokines otherwise known as the senescence-associated secretory phenotype, or SASP [18, 19].”
Moreno, A., Soleto, I., García‐Sanz, P., Moreno‐Bueno, G., & Palmero, I. (2013) · Oncogene · doi:10.1038/onc.2013.145 · Cited by 18
Ewald, J. A., & Jarrard, D. F. (2012) · Translational Oncology · doi:10.1593/tlo.12181 · Cited by 22
“Other characteristics of senescence have been used as surrogate markers including DNA damage and damage response signaling activities [5–7], secreted signaling factors [8], and other marker genes including Maspin and Cspg2 [9,10].”
MethodThe Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 24
“The senescence-associated secretory phenotype is induced principally by oncogenic stress, NF-κB in response to damaged DNA, and developmental cues, which initiates the IL-6, IL-8, IL1β, and TNF-α transcription [45].”
BackgroundMa, Y., Li, S., Ye, S., Hu, D., Wei, L. J., & Xiao, F. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113645 · Cited by 18
Kellers, F., Fernandez, A., Konukiewitz, B., Schindeldecker, M., Tagscherer, K. E., Heintz, A., Jesinghaus, M., Roth, W., & Foersch, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.865230 · Cited by 23
Alberro, A., Osorio-Querejeta, I., Sepúlveda, L., Fernández‐Eulate, G., Mateo‐Abad, M., Muñoz‐Culla, M., Carregal‐Romero, S., Matheu, A., Vergara, I., de Munaín, A. L., et al. (2019) · Aging · doi:10.18632/aging.102517 · Cited by 23
“One of the consequences of SASP is the chronic low-grade inflammation seen in the elderly, the so called inflammaging [21].”
BackgroundInfluentialKandhaya‐Pillai, R., Hou, D., Zhang, J., Yang, X., Compoginis, G., Mori, T., Tchkonia, T., Martin, G. M., Hisama, F. M., Kirkland, J. L., et al. (2021) · GeroScience · doi:10.1007/s11357-020-00318-6 · Cited by 21
Mahoney, S. A., Dey, A. K., Basisty, N., & Herman, A. B. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00352.2023 · Cited by 21
The induction of the fibroblast extracellular senescence metabolome is a dynamic process
James, E. N., Bennett, M. H., & Parkinson, E. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-29809-5 · Cited by 17
Luo, Y., Liu, H., Fu, H. Y., Ding, G., & Teng, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974377 · Cited by 19
Exploring the anti-aging effects of fisetin in telomerase-deficient progeria mouse model
Zhao, R., Kou, H., Jiang, D., & Wang, F. (2023) · PeerJ · doi:10.7717/peerj.16463 · Cited by 18
“…of CDK inhibitors (particularly p16 INK 4 a and p21 CIP 1 ), DNA damage accumulation, formation of senescence-associated heterochromatin foci, elevated intracellular ROS levels, and high levels of SASP factors ( Coppe et al., 2008 ), among others ( Lopez-Otin et al., 2023 ; Summer et al., 2019 ).”
BackgroundAlleviation of ginsenoside Rg1 on hematopoietic homeostasis defects caused by lead-acetate
Cai, S., Zhou, Y., Liu, J., Li, C., Jia, D., Zhang, M., & Wang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.148 · Cited by 18
Extracellular matrix and cellular senescence in venous leg ulcers
Lim, D. X. E., Richards, T., Kanapathy, M., Sudhaharan, T., Wright, G. D., Phillips, A. R. J., & Becker, D. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-99643-9 · Cited by 21
Nickless, A., Cheruiyot, A., Flanagan, K. C., Piwnica-Worms, D. R., Stewart, S. A., & You, Z. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.787846 · Cited by 17
Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer
Dai, L., Wang, X., Bai, T., Liu, J., Chen, B., & Yang, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.909546 · Cited by 19
Wang, X., Shi, W., Wang, K., Ye, Z., Wang, R., Wang, H., Yang, H., Xie, Z., Yu, H., & Wang, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00503 · Cited by 20
Fotopoulou, F., Rodriguez-Correa, E., Dussiau, C., & Milsom, M. D. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104698 · Cited by 19
Sakai, T., Takagaki, H., Yamagiwa, N., Ui, M., Hatta, S., & Imai, J. (2021) · Antioxidants · doi:10.3390/antiox10091398 · Cited by 17
Small airway disease as a key factor in COPD: new perspectives and insights
Zhou, R., Wang, H., Zhang, Y., Mai, J., & Yang, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1648612 · Cited by 19
Drugs that target aging: how do we discover them?
Myers, A., & Lithgow, G. J. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1597049 · Cited by 19
“Irrespective of cell type or underlying trigger for senescence, cells exhibiting a SASP secrete cytokines and chemokines such as interleukins (IL)-6 and −8, which through paracrine signaling exacerbate the growth and aggressiveness of nearby precancerous and cancerous cells [32,33].”
BackgroundTan, D., Huang, Z., Zhao, Z., Chen, X., Liu, J., Wang, D., Deng, Z., & Li, W. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5326 · Cited by 20
“Senescent MSCs release pro‑inflammatory cytokines that mediate cartilage damage and apoptosis and can partially alleviate cartilage damage by modulating miRNAs expression.”
BackgroundInfluential
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.